See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

Could Byetta Become a Standalone Drug?

Craig Eberhard

Could Byetta Become a Standalone Drug?

A Product For When You Have Low Blood Sugar

Bill Abajian

A Product For When You Have Low Blood Sugar

Todd speaks about Levemir

Todd Hobbs

Todd speaks about Levemir

Victoza Archives

Victoza

Page 2
Type 2 Drug Victoza Helps Type 1s, Too

Victoza, a drug aimed at type 2 diabetes, may turn out to be a boon for type 1 diabetes patients as well. A small clinical study shows that patients with well-controlled type 1 who took Victoza daily for just one week experienced a 15 percent drop in their blood sugar levels. Patients who took the drug over a full 24-week test period needed less and less insulin, decreasing their average mealtime dose by seven units and their all-day insulin requirement by eight.

Comments 2 comments - Jul 11, 2011 - * * * * *

Sanofi Says Late-Stage Trial of Type 2 Drug a Success

French drug maker Sanofi-aventis says that results from a Phase III trial of its experimental type 2 diabetes drug lixisenatide show that the drug successfully lowered patients' blood glucose levels and body weight, but did not increase the risk of hypoglycemia.

Comments 0 comments - May 23, 2011 - * * * * *

Victoza® Achieved Improved Blood Sugar Control in African-Americans With Type 2 Diabetes

Novo Nordisk presented results demonstrating that once-daily Victoza® (liraglutide [rDNA] injection) achieved significantly greater improvements in blood sugar control compared to placebo among African-American patients with type 2 diabetes. The meta-analysis of phase 3 data from the Liraglutide Effect and Action in Diabetes (LEAD) trials were presented at the 2010 National Medical Association Annual Convention & Scientific Assembly.

Comments 0 comments - Aug 5, 2010 - * * * * *

FDA Gives Novo the Go-Ahead to Market Victoza® in the U.S.

Danish pharmaceutical company Novo Nordisk has received Food and Drug Administration permission to begin marketing its type 2 drug Victoza® in the United States.
Victoza, the brand name for liraglutide, is a GLP-1* analog that is taken one a day by injection to help control blood sugar-and in some cases, help with weight loss-in patients with type 2 diabetes.

Comments 5 comments - Feb 27, 2010 - * * * * *

Novo, Upping the Ante in the Race for an Oral GLP-1 Drug, Tests a Pill Version of Victoza

Denmark-based Novo Nordisk has begun a Phase 1 trial of a pill form of a GLP-1 drug very similar to its Victoza product. The trial will involve  155 British patients with type 2 diabetes. The test on human subjects, although very early-stage,  puts the company in the lead to develop an oral form of a GLP-1 drug.

Comments 0 comments - Feb 1, 2010 - * * * * *

Novo Nordisk's Victoza Receives FDA Approval for the Treatment of Type 2 Diabetes

Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza (liraglutide injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.

Comments 4 comments - Jan 28, 2010 - * * * * *

Type 2 Drugs: EU Approves “Victoza,” FDA Extends Review of “Onglyza”

The European Union's drug regulation agency has recommended that the EU approve the marketing of "Victoza" (liraglutide), a type 2 drug developed by Novo Nordisk.

Comments 2 comments - May 6, 2009 - * * * * *

« Previous Page
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.